Adipotide
A peptidomimetic that targets and destroys blood vessels feeding white adipose tissue, causing fat cell apoptosis. Originally developed for cancer research.
Common Dosage
0.5mg - 1mg daily (Research)
Category
Fat Loss
- Targeted fat cell destruction
- Rapid fat loss
- Metabolic improvement
Adipotide (FTPP, or Prohibitin-targeting peptide-1) was discovered by Renata Pasqualini and Wadih Arap at MD Anderson Cancer Center during research into tumor vasculature-targeting peptides. They identified a peptide that homes to blood vessels feeding white adipose tissue and, when conjugated with a pro-apoptotic domain, destroys those vessels — causing fat cell death from ischemia. A landmark 2011 Nature Medicine paper demonstrated dramatic fat loss in obese rhesus monkeys, generating significant excitement.
Adipotide consists of two functional domains: one targeting prohibitin on adipose endothelial cells and one pro-apoptotic sequence (KLAKLAK)2 that destroys mitochondria. When the peptide homes to adipose vasculature, it triggers endothelial apoptosis, cutting off blood supply to fat cells and causing their death. This is fundamentally different from any other weight loss mechanism — it literally destroys the fat-feeding blood vessels rather than reducing food intake or increasing metabolism.
- Severe obesity — primate models showing rapid fat mass reduction
- Refractory obesity research
- Understanding adipose vascular biology
- Combination weight management research
Primate Study (Nature Medicine 2011)
Obese rhesus monkeys treated with adipotide lost an average of 11% body weight and 27% visceral fat over 28 days — dramatic results accompanied by improved insulin sensitivity. The results directly paralleled the researchers' hypotheses, validating the mechanism in a primate model.
- Significant kidney stress is documented in the primate study — reversible but concerning kidney function decline was observed in all treated animals
- Hydration requirements are critical — dehydration dramatically increases renal risk
- The mechanism (vascular destruction) is fundamentally irreversible in individual fat depots — unlike metabolic approaches, this physically destroys tissue
- Mechanism concerns regarding collateral vascular damage in nearby tissue
- No human clinical trials have been completed — risk profile in humans is unknown
- Among the highest risk peptides in the research space — should be approached with extreme caution and monitoring
- Kidney stress
- Dehydration
- Fatigue